close-up photo of a man wearing eyeglasses who is very interesed in whatever he is looking at

News Releases

February 18, 2021
Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis
February 11, 2021
Almirall Announces New England Journal of Medicine Publication of Phase III Data Demonstrating Efficacy and Safety of Klisyri® (tirbanibulin)
December 15, 2020
Almirall Announces FDA Approval of Klisyri® (tirbanibulin), a New Innovative Topical Treatment for Actinic Keratosis
November 18, 2020
Almirall appoints Pablo Alvarez as President and General Manager of US organization
June 18, 2020
Almirall Announces FDA Approval Of Updated Label For SEYSARA® (sarecycline) Tablets
January 9, 2020
Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
January 9, 2020
Almirall Signs A Strategic Agreement With 23andMe To License Rights Of A Bispecific Monoclonal Antibody That Blocks All Three Isoforms Of IL-36 Cytokine
January 8, 2020
Almirall Enters Into an Option Agreement to Acquire Bioniz Therapeutics and to Establish a Broad Research Agreement to Further Expand Its Innovative Pipeline in Medical Dermatology
December 6, 2019
Almirall LLC Announces The Publication Of Long-Term Safety Data For The Use Of Seysara® (sarecycline) Tablets In Patients 9 Years Of Age And Older
September 10, 2019
ACZONE® (dapsone) GEL, 7.5% Now Approved For The Topical Treatment Of Acne Vulgaris In Patients 9 Years Of Age And Older
July 25, 2019
Almirall Issues Call for Grant Submissions for Development of New Immunodermatology Therapies through Almirallshare
June 17, 2019
Almirall Partners with AARS to Raise Awareness about the Burden of Disease and Importance of Education for Dermatology Professionals for National Acne Awareness Month
May 13, 2019
Almirall Q1 2019. Strong operating performance
April 11, 2019
Almirall Recognized As Distinguished Corporate Leader By American Skin Association - Unveiled Patient-Driven Purpose
March 4, 2019
Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
March 4, 2019
Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business
January 17, 2019
Novel Oral Antibiotic SEYSARA™ (sarecycline) Now Available
October 19, 2018
Almirall LLC Launches New Name at Fall Clinical Dermatology Congress
September 21, 2018
Almirall acquires Allergan U.S. medical dermatology portfolio

Media Inquiries
media.us@almirall.com

Almirall PR
almirallpr.us@almirall.com

Privacy Policy       Terms of Use
Contents © 2005-2021 Almirall, LLC, Malvern, PA 19355, 10/18 USPHA0087(2)b All Rights Reserved.